PHX — Pharmx Technologies Income Statement
0.000.00%
Last trade - 00:00
- AU$29.93m
- AU$17.78m
- AU$6.13m
- 56
- 72
- 87
- 81
2019 June 30th | 2020 June 30th | R2021 June 30th | R2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 11.2 | 10.6 | 11.9 | 5.38 | 6.13 |
Cost of Revenue | |||||
Gross Profit | 10.1 | 9.44 | 10.3 | 4.56 | 4.92 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15.2 | 11.9 | 12.1 | 5.26 | 6.79 |
Operating Profit | -3.98 | -1.27 | -0.247 | 0.127 | -0.665 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.98 | 0.458 | 1.35 | 0.122 | -0.719 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.21 | 0.176 | 1.08 | -0.131 | -0.883 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -4.21 | 0.176 | 1.09 | 0.252 | -1.05 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.21 | 0.176 | 1.09 | 0.252 | -1.05 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.005 | 0.003 | 0.002 | -0 | -0.001 |